MedTrace Logo

Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

NCT00182052 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2013-05-23

No results posted yet for this study

Summary

The purpose of this study it to learn the effects (good or bad) that rosiglitazone has on patients and their prostate cancer. This study is going to look at what effects rosiglitazone has on prostate specific antigen (PSA) levels.

Conditions

Interventions

DRUG

Rosiglitazone

Given orally twice daily. Participants may continue study treatment as long as their disease does not progress and they don't experience any serious side effects.

OTHER

Placebo

Given orally twice daily.

Sponsors & Collaborators

Principal Investigators

  • Matthew Smith, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-09-30
Primary Completion
2003-08-31
Completion
2003-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00182052 on ClinicalTrials.gov